Skip to main content
. Author manuscript; available in PMC: 2019 Dec 1.
Published in final edited form as: Expert Rev Anticancer Ther. 2018 Oct 9;18(12):1249–1270. doi: 10.1080/14737140.2018.1527688

Figure 2:

Figure 2:

The phylogenetic map of the human kinome demonstrating development and US FDA approval of small molecule kinase inhibitors to tyrosine kinases and serine/threonine kinases for a variety of solid and hematologic malignancies. Other kinome family members under active clinical investigation include NTRK-fusion activated kinase, CDK8, and ERK1/2.